Datwyler a provider of system-critical elastomer components, announced a collaboration with LTS Device Technologies, a developer of smart wearable devices for drug delivery, and Stevanato Group, a provider of drug containment, drug delivery, and diagnostic solutions.
Together the companies aim to broaden the scope of large-volume subcutaneous drug delivery by enabling convenient on-body administration of larger volumes – meeting the evolving needs of patients, alongside market demands.
Supporting Patient-Centric Healthcare for Large-Volume Self Administration
The pharmaceutical landscape for subcutaneous drug delivery is undergoing rapid transformation, driven by the increasing use of biologics and other sensitive therapeutics in clinical practice. According to Precedence Research, the U.S. biologics market is projected to reach $483 billion by 2034, as small molecule research and development productivity declines.
At the same time, patient preferences are changing. A recent Mayo Clinic study (Mayo Clinic's) found that 73% of participants favored in-home self-administration after 24 weeks of therapy – underscoring the need for solutions that support decentralized, convenient patient-centric healthcare versus hospitals or other medical settings.
"By enabling patients to self-administer therapies at home, subcutaneous drug administration facilitates a growing shift towards more accessible personalized healthcare. Datwyler's spray coated NeoFlex™ plungers increase the functional reliability of large volume injection systems and promote greater comfort and safety for the patients," said Paolo Ferrigno, Product Manager, PFS & Cartridges, Datwyler.
Overcoming the Challenges of On-body Delivery for Large-Volume Therapies
Transitioning from hospital-based administration to at-home delivery for large volume, highly sensitive biologics, and other formulations present unique challenges, such as:
- Pain, tissue tolerability, and absorption kinetics for high-volume therapies have limited subcutaneous injections to lower volumes, typically 2mL or less.
- High-dose therapies, such as monoclonal antibodies, oncology treatments, and long-acting neurologic formulations, often exceed the limits of conventional low-volume delivery.
- The design of a new custom delivery solution may not always be feasible for pharmaceutical and medical device manufacturers in a competitive market.
Riccardo Marcon, Senior Vice President Sales & Marketing of Drug Containment Solutions with Stevanato Group commented, "There is a pressing market need for innovative solutions to support larger volumes of up to 20mL in a self-administered setting while strictly maintaining safety, therapeutic efficacy, and patient compliance. For pharma companies, EZ-fill® Large Volume Cartridges have been the ideal solution to reduce their complex operations for more than a decade. Our market-leading ready-to-use, EZ-fill® containers are supplied pre-washed, pre-siliconized, pre-assembled with front stoppers, packed in Nest & Tub and pre-sterilized."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!